TORONTO, Aug. 14,
2023 /CNW/ - Think Research Corporation (TSXV: THNK)
("TRC" or the "Company"), a company focused on
transforming healthcare through digital health software solutions,
today announced the results of its August
11, 2023 Annual General Meeting (the "Meeting") of
shareholders. The Company is pleased to announce the following 7
directors have been re-elected to Think's Board of Directors:
Sachin Aggarwal, Cindy Gray, Eric
Hoskins, Barry Reiter,
Abe Schwartz, Kirstine Stewart and Richard Wells. At the Meeting, Think's
shareholders also voted in favour of the appointment of Ernst &
Young LLP, Chartered Accountants, as Think's auditor. Think's
shareholders ratified and approved the Company's omnibus long-term
incentive plan (the "Plan") as described in Schedule D of
Think's management information circular dated June 27, 2023. The Plan is a rolling 10% plan,
which as of August 11, 2023 has a
total of 7,810,823 issuable under the Plan, of which 7,351,952 are
subject to existing awards under the Plan. Final acceptance of the
Plan by the TSX Venture Exchange is pending. Think's shareholders
rejected the shareholder proposal as described in Schedule G
of Think's management information circular.
On August 1st, 2023 the Company
announced a share for debt transaction. The total number of shares
exchanged for debt was 173,826 common shares.
About Think Research
Corporation
Think Research Corporation is an industry leader in delivering
knowledge-based digital health software solutions. The Company's
focused mission is to organize the world's health knowledge so
everyone gets the best care. Its evidence-based healthcare
technology solutions support the clinical decision-making process
and standardization of care to facilitate better health care
outcomes. The Company gathers, develops, and delivers
knowledge-based solutions globally to customers including
enterprise clients, hospitals, health regions, healthcare
professionals, and / or governments. The Company has gathered a
significant amount of data by building its repository of knowledge
through its network and group of companies.
Think licenses its solutions to over 14,200 facilities for over
320,000 primary care, acute care, and long-term care doctors,
nurses and pharmacists that rely on the content and data provided
by Think to support their practices. Millions of patients and
residents annually receive better care due to the essential data
that Think produces, manages and delivers.
In addition, the Company collects and manages pharmaceutical and
clinical trial data via its BioPharma Services subsidiary.
BioPharma Services is a leading provider of bioequivalence and
Phase 1 clinical research services to pharmaceutical companies
globally. Think's other services include a network of digital-first
primary care clinics and medical clinics that provide elective
surgery. Visit www.thinkresearch.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
For more
information: https://www.thinkresearch.com/ca/investors/
SOURCE Think Research Corporation
